ReviewAnnals of surgery2010
Clinical operational tolerance after renal transplantation: current status and future challenges.
Review in Annals of surgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Pooled it
- A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft.Kidney international · 2015Pooled it
- Review
- Autologous immune system reset for kidney allograft acceptance: mechanisms, evidence, and a testable reconstitution-window model.Frontiers in medicine · 2026Review
- Redefining the Immunobiology of Organ Transplantation for New Clinical Horizons.Scandinavian journal of immunology · 2025Review
- Enhanced Costimulation Blockade With αCD154, αCD2, and αCD28 to Promote Heart Allograft Tolerance in Nonhuman Primates.Transplantation · 2025Article
- Exploring Costimulatory Blockade-Based Immunologic Strategies in Transplantation: Are They a Promising Immunomodulatory Approach for Organ and Vascularized Composite Allotransplantation?Journal of personalized medicine · 2024Review
- Contemporary Biomarkers for Renal Transplantation: A Narrative Overview.Journal of personalized medicine · 2023Review
- Revisiting transplant immunology through the lens of single-cell technologies.Seminars in immunopathology · 2023Review
- Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Review
- Operational tolerance in intestinal transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- The Role of Systems Vaccinology in Understanding the Immune Defects to Vaccination in Solid Organ Transplant Recipients.Frontiers in immunology · 2020Review
- Bioprinting an Artificial Pancreas for Type 1 Diabetes.Current diabetes reports · 2019Review
- Delivery of Rapamycin Using In Situ Forming Implants Promotes Immunoregulation and Vascularized Composite Allograft Survival.Scientific reports · 2019Article
- Biomarkers and Pharmacogenomics in Kidney Transplantation.Molecular diagnosis & therapy · 2018Review
- Mechanisms and biomarkers of immune quiescence in kidney transplantation.Human immunology · 2018Review
- Reduced TCR Signaling Contributes to Impaired Th17 Responses in Tolerant Kidney Transplant Recipients.Transplantation · 2018Article
- Operational tolerance in kidney transplantation and associated biomarkers.Clinical and experimental immunology · 2017Review
- Comparative Analyses of Signature Genes in Acute Rejection and Operational Tolerance.Immune network · 2017Article
Corrections and comments
- Erratum issuedCocco, Pierpaolo Di [corrected to Di Cocco, Pierpaolo]
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
In solid organ transplantation, the achievement of an immunosuppression (IS)-free state [also referred to as clinical operational tolerance (COT)] represents the ultimate goal. Although COT is feasible and safe in selected cases after liver transplantation, it is an exceptional finding after other types of solid organ transplantation. In the field of renal transplantation (RT), approximately 100 cases of COT have been reported to date, mainly in patients who were not compliant with their immunosuppressive regimens or in individuals who had previously received a bone marrow transplant for hematological disorders. On the basis of promising results obtained in animal models, several tolerogenic protocols have been attempted in humans, but most have failed to achieve robust and stable COT after RT. Molecule-based regimens have been largely ineffective, whereas cell-based regimens have provided some encouraging results. In these latter regimens, apart from standard IS, patients usually receive perioperative infusion of donor bone marrow-derived stem cells, which are able to interact with the immune cells of the host and mitigate their response to engraftment. Unfortunately, most renal transplant patients who developed acute rejection-occurring either during the weaning protocol or after complete withdrawal of IS-eventually lost their grafts. Currently, the immune monitoring necessary for predicting the presence and persistence of donor-specific unresponsiveness is not available. Overall, the present review will provide a conceptual framework for COT and conclude that stable and robust COT after RT remains an elusive goal and that the different strategies attempted to date are not yet reproducibly safe or effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.